Skip to content

March 24-26, 2020
San Diego, CA

Improving Patient Care by Advancing Innate Understanding & Enhancing Innate Cell Therapies

Media Hub

Exclusive Speaker Interview: Patrick Soon-Shiong

Patrick Soon-Shiong

Chairman & CEO

NantKwest

Preview:

How and to what capacity are you involved with developing NK cell therapies?

NantKwest develops our universal, off-the-shelf natural killer cell platform. This has been engineered to express a high-affinity CD16 for targeted antibodydependent cellular cytotoxicity (ADCC) in combination with IgG1 monoclonal antibodies. These haNK cells are in phase II trials in merkel cell cancer as part of a combination therapy. Cells also have been engineered to express chimeric antigen receptors (CARs) against various tumor antigens. NantCell is focused on the development of a bispecific NK and T cell activation molecule (N-803), which consists of an IL-15 / IL-15 receptor alpha complex that is linked to an IgG1 Fc (a ligand of CD16). This fusion protein has demonstrated an ability to activate and expand NK and CD8+ T cell populations without expanding regulatory T cell populations. N-803 is currently being studied in combination with BCG in a phase II trials in BCG-unresponsive non-muscle invasive bladder cancer, as well as and in combination with anti-PD-1 antibodies in NSCLC and other solid tumors. In addition, NantCell also is further modifying this IL-15-based fusion protein to target additional molecules, such as PD-L1....

Development of novel NK cell-specific chimeric antigen receptors to improve anti-tumor activity.


Dan S.Kaufman at University of California, School of Medicine

image

Tumour-mediated NK priming for cancer immunotherapy.


Mark Lowdell at University College London

Mark Lowdell

Engineering NK cells to target the inhibitory solid tumor microenvironment.

Robin Parihar at Baylor College of Medicine

Robin Parihar

NKTR-255: Accessing The Immunotherapeutic Potential of IL-15 for NK Cell Therapies.


Saul Kivimäe at Nektar Therapeutics

Saul Kivimae